UAE healthcare experts are examining the broader medical potential of GLP-1 treatments, highlighting that these medications may offer advantages beyond weight reduction and could support wider health improvements.
UAE Doctors Explore Wider Health Benefits of GLP-1 Medicines Beyond Weight Management.
As research on Ozempic-type drugs continues to expand, specialists suggest these medications could have effects across various areas of the body, but emphasise that they should only be used with appropriate medical guidance and monitoring.
For many patients, GLP-1 medications have become widely recognised because of their strong association with weight management and significant weight reduction. However, healthcare specialists in the UAE say the effects of these treatments may extend far beyond changes seen on the weighing scale.
As scientific research continues to develop and doctors gain more experience using these medicines in clinical settings, evidence is emerging that GLP-1 therapies may provide benefits for several important areas of health. These medications, which were initially introduced mainly for managing diabetes, are now being studied for their potential role in supporting cardiovascular health, improving metabolic conditions, and protecting vital organs.
Medical experts explain that GLP-1 receptor agonists work by influencing several processes within the body, including blood sugar regulation, appetite control, and metabolism. Their wider impact has increased interest among researchers and physicians who are examining how these treatments may help patients beyond their original purpose.
Dr Julie Shah, Consultant in Endocrinology and Obesity Medicine at Sheikh Shakhbout Medical City (SSMC) in Abu Dhabi, said that the value of GLP-1 receptor agonists should not be measured only by their ability to help people lose weight.
According to Dr Shah, these medications offer additional health advantages that may have a meaningful impact on patients with metabolic disorders. She explained that research has shown potential improvements in areas connected to heart health, blood sugar control, and complications associated with chronic conditions.
One of the major areas of interest is cardiovascular health. Studies have indicated that GLP-1 medicines may help reduce factors linked to inflammation and cardiovascular risk. Doctors say this could be important because people living with obesity or diabetes often face a higher likelihood of developing heart-related conditions.
Experts note that these therapies may contribute to lowering the risk of serious cardiovascular events, including heart attacks, strokes, and complications related to heart failure. By improving metabolic health and supporting better management of risk factors, GLP-1 medications are becoming an important area of research in preventive healthcare.
Another significant benefit being examined is their role in improving glucose regulation. Since these medications were originally developed for diabetes management, their ability to support healthier blood sugar levels remains one of their primary functions.
Doctors say GLP-1 treatments can help improve how the body processes glucose and may assist patients in achieving better control over blood sugar levels. For individuals at risk of developing type 2 diabetes, ongoing research is exploring whether these medications could help delay or reduce disease progression when combined with appropriate lifestyle changes.
The potential effects of GLP-1 therapies on liver health have also attracted attention. Metabolic liver conditions, which are often linked to obesity, insulin resistance, and lifestyle factors, are becoming increasingly common worldwide. Researchers are investigating whether these medications may help reduce some of the metabolic changes associated with liver disease.
Early evidence suggests that improvements in weight, insulin sensitivity, and metabolism may have positive effects on liver function. While research is still developing, doctors believe this area could become an important part of future treatment approaches for patients with metabolic-related liver problems.
Kidney health is another area where researchers are exploring possible benefits. People with diabetes and metabolic disorders often face an increased risk of kidney complications. Some studies suggest that GLP-1 medications may provide protective effects by improving metabolic factors that contribute to kidney damage.
Healthcare professionals stress that while these findings are encouraging, these medicines should not be viewed as a universal solution or used without medical advice. Proper evaluation, monitoring, and guidance from qualified doctors remain essential to ensure safe and effective treatment.
Doctors explain that every patient’s situation is different, and the decision to use GLP-1 medications depends on individual health conditions, medical history, and treatment goals. These therapies may provide significant benefits for some patients, but they require appropriate supervision to manage potential side effects and ensure the best outcomes.
The growing interest in GLP-1 drugs reflects a broader change in how doctors approach conditions such as obesity and diabetes. Rather than focusing only on weight reduction, medical professionals are increasingly looking at the wider impact of these diseases on the body and how treatments can improve overall health.
Experts say the future of GLP-1 medications may involve broader applications as research continues to uncover their possible effects on different organ systems. Their role in healthcare is evolving from being viewed mainly as weight-loss treatments to becoming part of a larger strategy for managing complex metabolic conditions.
For patients, this means the conversation around GLP-1 therapies is becoming more comprehensive. The focus is shifting from appearance or weight alone toward improving long-term health, reducing disease risks, and supporting better quality of life.
As more studies are completed and clinical experience expands, doctors expect a clearer understanding of the full potential of these medications. For now, specialists emphasise that the benefits of GLP-1 treatments appear promising, but responsible use and professional medical guidance remain essential.
The growing interest in GLP-1 medications reflects a broader change in how doctors and researchers view this category of treatments. Drugs such as semaglutide and tirzepatide were initially developed and widely used to help manage type 2 diabetes by improving blood sugar control. However, their popularity increased significantly after they became associated with major weight-loss results through well-known brands including Ozempic and Mounjaro.
In recent years, public discussions around these medications have largely focused on their ability to support weight reduction. Media coverage, celebrity experiences, and online conversations have contributed to their rapid rise in popularity. At the same time, concerns about possible side effects, accessibility, and appropriate use have also become part of the wider conversation.
However, medical professionals say the public image of these treatments represents only one part of their potential. Healthcare experts are increasingly examining how GLP-1 therapies may influence several areas of health beyond weight management, including metabolic function and chronic disease control.
Doctors explain that the scientific understanding of these medicines continues to develop as more research becomes available. What was once viewed mainly as a treatment option for diabetes is now being studied for a wider range of possible applications, creating new interest among specialists.
Hala Zakaria, Innovation, Research and Operations Manager at Metabolic, formerly GluCare.Health, said the role of this drug category continues to expand as evidence grows. She noted that researchers and clinicians are discovering additional possibilities for these therapies, leading to a broader understanding of their impact on patient health.
According to Zakaria, the medical community is moving toward a more complete view of GLP-1 medications rather than focusing only on their effect on body weight. Their potential benefits, combined with advances in research and clinical experience, are helping shape a new perspective on how these treatments may be used in the future.
As studies continue, experts believe the significance of GLP-1 medicines may extend well beyond their original purpose. The increasing focus on their wider health effects highlights the evolving role of these therapies in modern medicine and the importance of using them under proper medical supervision.
Hala Zakaria.
When GLP-1 medications were initially introduced, their primary purpose was focused on improving blood sugar management for people living with diabetes. Early discussions around these treatments largely centred on their ability to regulate glucose levels and support better control of the condition.
However, as scientific research expanded and more clinical trials were completed, the understanding of these medicines changed significantly. New findings revealed that their impact could extend beyond diabetes management, opening the door to a wider range of potential health benefits.
Over time, approvals from health regulators and results from large-scale studies have shown that GLP-1 therapies may provide additional advantages for patients with certain medical conditions. Researchers have found evidence suggesting these medications may help reduce cardiovascular risks among people with type 2 diabetes, which is particularly important because diabetes is often linked with a higher chance of developing heart-related complications.
Studies have also highlighted possible protective effects on kidney health, especially with medications such as semaglutide. This has increased interest among doctors who are exploring how GLP-1 treatments could support patients facing complications associated with metabolic diseases.
Beyond their effects on blood sugar and weight, these medicines are also being examined for their role in other health conditions. Researchers are investigating their potential in managing metabolic dysfunction-associated steatohepatitis (MASH), a liver condition associated with fat accumulation and metabolic problems.
Another area gaining attention is obstructive sleep apnoea, a condition often connected with obesity and metabolic health challenges. Emerging research suggests that improvements in weight and metabolic function may contribute to better outcomes for some patients affected by this disorder.
Healthcare specialists say the expanding evidence has changed the way these medications are viewed. Rather than being considered only diabetes treatments or weight-management tools, GLP-1 therapies are now being studied as part of a broader approach to addressing multiple interconnected health issues.
Experts emphasize that continued research will help determine the full range of benefits and the most effective ways to use these medicines. While the results so far are promising, doctors stress that treatment decisions should always be based on individual patient needs and conducted under proper medical supervision.
The growing body of evidence demonstrates how the role of GLP-1 medications has evolved over time. What began as a therapy focused on glucose control has developed into a wider area of medical research, with potential applications across several aspects of metabolic and chronic disease care.
Beyond the number on the scale
Evidence from patients in the UAE is increasingly reflecting global research suggesting that GLP-1 medications may have effects that go beyond simple weight reduction. Local healthcare data indicates that these treatments could support broader improvements in metabolic health, including better blood sugar control, improved cholesterol levels, and reductions in several risk factors linked to chronic diseases.
A 2025 outcomes analysis conducted by Metabolic reviewed the progress of 2,310 patients who participated in diabetes, pre-diabetes, and weight-management programmes at its Dubai clinics. The review covered patients receiving care between January and December of the previous year and examined changes in health indicators beyond changes in body weight.
The findings suggested that patients experienced improvements across multiple areas of health, highlighting the possibility that GLP-1-based treatment programmes may influence a wider range of metabolic conditions. While weight reduction remained one of the noticeable outcomes, healthcare providers observed additional changes related to cardiovascular risk factors, blood sugar regulation, and overall wellbeing.
Among patients enrolled in the pre-diabetes programme, improvements were seen not only in glucose levels but also in several important metabolic measurements. Some participants who had previously been classified as having pre-diabetes achieved normal blood sugar readings, while also showing reductions in markers associated with increased health risks.
The report indicated decreases in triglyceride levels, low-density lipoprotein (LDL) cholesterol, total cholesterol, and certain liver-related indicators. These changes are significant because elevated cholesterol and abnormal metabolic markers are often associated with a higher likelihood of developing cardiovascular disease and other long-term health complications.
Doctors explain that pre-diabetes is often considered a warning stage where lifestyle changes and medical interventions can play an important role in preventing progression to type 2 diabetes. Improvements in metabolic indicators may therefore represent an important step toward reducing future health risks.
The outcomes observed in weight-management programmes also showed benefits beyond changes on the scale. According to the report, participants experienced reductions in triglyceride levels after six months of treatment, with average decreases of around 20.8 mg/dL.
In addition to measurable changes in clinical indicators, patients reported improvements in areas affecting daily life. These included better movement and mobility, reduced discomfort and pain, improved sleep-related outcomes, and positive changes in mental wellbeing.
Healthcare experts say these findings reflect a broader understanding of obesity and metabolic conditions. Rather than viewing weight as an isolated issue, specialists increasingly recognise that excess weight is often connected with a range of health challenges, including inflammation, insulin resistance, cardiovascular risks, and sleep disorders.
Research published by Metabolic examining the use of semaglutide and tirzepatide within a structured healthcare programme also reported encouraging outcomes. The analysis found that some patient groups achieved metabolic syndrome reversal rates above 50 per cent.
Metabolic syndrome is a collection of health problems that often occur together, including increased body fat around the waist, high blood pressure, elevated blood sugar levels, and unhealthy cholesterol patterns. Having multiple of these conditions at the same time increases the risk of developing serious illnesses such as heart disease and type 2 diabetes.
Experts say reducing the factors associated with metabolic syndrome is an important goal because these conditions often interact with one another. Improving one area, such as blood sugar control or weight management, can have positive effects across several aspects of health.
The research involving UAE patients also provided further insight into how these treatments may affect measurable health outcomes. Among 51 individuals receiving care, researchers observed reductions in waist size, triglyceride levels, and diastolic blood pressure over a six-month period.
Changes in waist circumference are considered an important indicator because abdominal fat is closely linked with metabolic problems. Similarly, improvements in blood pressure and triglyceride levels may contribute to reducing long-term cardiovascular risks.
Medical professionals note that while the results are promising, GLP-1 medications are most effective when combined with a comprehensive approach that includes medical supervision, lifestyle adjustments, nutrition guidance, and regular monitoring.
The UAE data adds to the growing international discussion about the expanding role of GLP-1 therapies. Originally developed mainly for diabetes management, these medications are now being explored for their potential to address multiple interconnected health concerns.
Researchers continue to study how these treatments affect different patient groups and which individuals are most likely to benefit. Experts emphasise that outcomes can vary depending on factors such as existing health conditions, treatment plans, and individual responses.
The findings from local programmes suggest that the impact of GLP-1 medications may extend beyond the traditional focus on weight loss. Improvements in metabolic markers, cardiovascular risk factors, and quality-of-life measures indicate that these therapies may represent a broader tool in managing complex health conditions.
As research continues, healthcare providers expect a deeper understanding of how these medications can be used safely and effectively. For now, specialists stress that their role should be considered as part of a wider healthcare strategy rather than a standalone solution.
The growing evidence from both international studies and UAE patient data highlights a shift in how these treatments are viewed. GLP-1 therapies are increasingly being recognised not only for their ability to support weight management but also for their potential contribution to improving overall metabolic health.
‘Regaining health’
For 49-year-old Brazilian expatriate Sheyla Sanches, who has built her career as a nursery manager in the UAE, her experience with GLP-1 treatment became a journey that transformed much more than her physical appearance.
When she first began using GLP-1 therapy nearly four years ago, her main objective was straightforward — to lose excess weight and improve her general health. At the time, she did not anticipate how deeply the treatment would influence other areas of her wellbeing or how significantly it would change her overall health condition.
Sanches said that during the course of her treatment, she lost more than 40 kilograms. While weight reduction was the most visible change, she explained that the biggest impact came from improvements in several health issues she had been dealing with before starting therapy.
Before beginning treatment, Sanches was managing multiple metabolic concerns, including insulin resistance, pre-diabetes, elevated cholesterol levels, fatty liver disease, and polycystic ovary syndrome (PCOS). These conditions had affected her health and required ongoing attention and management.
She explained that her progress was closely monitored by healthcare professionals through regular appointments, blood tests, and medical evaluations. This continuous supervision helped track how her body was responding and allowed her doctors to assess improvements beyond weight changes.
Over time, she began noticing significant improvements in her medical results. Her blood sugar levels improved and returned to normal ranges, while her insulin resistance showed considerable progress. She also experienced positive changes in her cholesterol levels, and tests indicated that her fatty liver condition had improved.
For Sanches, the most meaningful part of the experience was understanding that the changes were not only visible externally. She said the journey represented a deeper recovery of her health rather than simply a change in her body size.
Seeing improvements reflected in medical reports became an important moment for her because it confirmed that the treatment was helping address internal health challenges as well. The results showed progress that went beyond appearance and demonstrated improvements in key areas related to her overall wellbeing.
She highlighted that the success of her transformation was not based on medication alone. According to Sanches, regular medical guidance, consistent follow-up, and lifestyle adjustments were essential parts of her progress.
She said the treatment helped her regain confidence and take greater control of her health, but it also encouraged her to develop healthier habits. Through the process, she became more aware of her eating patterns, improved her approach to nutrition, and made exercise a regular part of her daily routine.
Sanches explained that the experience changed her relationship with food. Instead of focusing only on short-term weight loss, she learned to make more balanced choices and adopt habits that could support long-term health.
She believes the combination of medical support and personal commitment played a major role in achieving lasting improvements. The treatment gave her an opportunity to address health concerns that had previously affected her quality of life, while lifestyle changes helped maintain the progress she achieved.
Looking back on her experience, Sanches said GLP-1 therapy represented much more than a weight-loss method. For her, it became a pathway toward improving her health, reducing the impact of existing medical conditions, and creating a healthier lifestyle.
She emphasised that the most important outcome was not simply losing kilograms but gaining better control over her wellbeing. The improvement in her health markers gave her a renewed sense of confidence and motivation to continue prioritising her physical and mental health.
Her experience reflects the broader conversation around GLP-1 medications, where doctors and patients are increasingly exploring their potential role beyond weight management. While individual results vary and treatment requires professional supervision, some patients report improvements that extend into several aspects of their health.
For Sanches, the journey has been about rebuilding a healthier future. The changes she experienced have influenced how she approaches nutrition, exercise, and self-care, turning the treatment period into a long-term lifestyle transformation.
She said that the biggest lesson from her experience was understanding that health improvement involves consistent effort and ongoing commitment. The medication supported her progress, but the habits she developed along the way became an equally important part of maintaining her results.
Today, Sanches views her GLP-1 journey as a turning point that helped her move beyond managing health problems and toward achieving a better quality of life. For her, the treatment was not only about changing her weight — it was about restoring her health and creating a more sustainable future.
‘The food just stopped calling me’
For Sofiane, a 40-year-old French entrepreneur based in Dubai, starting GLP-1 therapy was not only about changing his weight. His decision was influenced by growing concerns about his overall health and the impact that his weight was having on his body.
At the time he began treatment, Sofiane weighed 132 kilograms and stood 191 centimetres tall. Along with concerns about obesity, he was dealing with several health issues, including fatty liver disease, sleep apnoea, high cholesterol, elevated levels of the liver enzyme GAMMA GT, and increased uric acid levels.
He said he had reached a point where he recognised that his health was moving in the wrong direction. Before considering GLP-1 treatment, he had already attempted different approaches, including changing his diet and exercising regularly, but he struggled to maintain long-term results.
“I had tried different diets and workout routines, but nothing seemed to last,” he explained. “I realised I needed a different approach.”
Although his main expectation when beginning treatment was to lose weight, Sofiane said the changes he experienced went beyond what he had imagined. One of the biggest surprises for him was the dramatic shift in his relationship with food.
He explained that the strongest cravings he previously experienced began to disappear. Foods that had once been a major part of his daily habits, including fast food, sugary products, soft drinks, and other high-calorie options, suddenly became far less appealing.
According to Sofiane, the change did not feel like a constant struggle or a battle against temptation. Instead, he described it as a natural change in his appetite and mindset, where the desire for certain foods simply became much weaker.
He said this was one of the most unexpected parts of his experience because he had previously found it difficult to control those eating habits through willpower alone. The reduction in cravings helped him make healthier choices more easily and maintain a more balanced approach to nutrition.
However, the most meaningful moment for him came when medical follow-up tests showed improvements in several health areas. While weight loss was visible, he said the changes revealed through medical assessments confirmed that the treatment was having a deeper effect.
Sofiane was particularly surprised by improvements in his liver-related health markers, GAMMA GT levels, and uric acid measurements. Seeing those indicators return to healthier levels showed him that the progress was not only reflected in his appearance but also in his internal health.
He said the results changed his perspective on obesity treatment. For him, the journey was no longer simply about reducing weight but about improving his overall wellbeing and addressing health problems that had previously affected his quality of life.
Over time, Sofiane’s weight dropped from 132 kilograms to 91 kilograms. While the physical transformation was significant, he believes the biggest change happened in the way he thinks about health, lifestyle, and daily choices.
He explained that GLP-1 treatment should not be viewed as an instant solution or an easy replacement for healthy habits. Instead, he sees it as a support tool that can help people make meaningful changes when combined with commitment and lifestyle adjustments.
According to Sofiane, the medication created an opportunity for change, but maintaining progress required a complete shift in behaviour. He focused on improving his relationship with food, becoming more aware of his habits, and making decisions that supported his long-term health.
He described the transformation as something that affected his mindset as much as his body. The process encouraged him to reconsider how he approached nutrition, energy, time, and personal wellbeing.
For Sofiane, the visible weight loss was only one part of the journey. The deeper impact came from understanding his health better and developing a more sustainable lifestyle.
He believes that successful treatment involves more than reaching a certain number on the scale. It requires changing the way people think about their bodies and building habits that can continue long after the initial weight-loss phase.
Reflecting on his experience, Sofiane said the biggest lesson was that GLP-1 therapy works best when combined with personal responsibility and long-term lifestyle improvements. The treatment helped him regain control, but the lasting transformation came from the changes he made along the way.
Today, he views his experience as a major turning point. What started as an effort to lose weight became a broader journey toward better health, improved confidence, and a different understanding of how lifestyle choices influence overall wellbeing.
For him, the real achievement was not only losing kilograms but creating a healthier relationship with food, improving his medical condition, and gaining a new perspective on maintaining a balanced life.
Health changes can begin before major weight reduction
Medical specialists say that the effects of GLP-1 medications may start appearing much earlier than many patients expect. While most people associate these treatments with visible weight loss, doctors explain that important changes inside the body can occur even before significant changes are noticed physically.
Dr Julie Shah said that improvements in metabolic health often develop during the early stages of treatment, sometimes before patients see major differences in their body weight. She explained that changes such as better blood sugar regulation, improved control over appetite, and a greater feeling of fullness can happen relatively quickly.
According to clinicians, these early responses indicate that GLP-1 therapies are influencing several biological processes beyond simply reducing food intake. The medications appear to affect metabolism, hormone activity, and other systems connected to long-term health.
Data from Metabolic’s patient programmes also showed a similar trend. Among individuals being treated for pre-diabetes, improvements in HbA1c levels were recorded within the first three months. Many participants reached healthier blood sugar ranges within six months, even though their average body mass index (BMI) reduction during that period was still moderate.
Hala Zakaria said these findings support the growing understanding that GLP-1 medications may have effects on the body beyond weight management. She explained that changes in important metabolic indicators often begin early in treatment, sometimes before patients reach the weight-loss levels commonly used by doctors to define significant progress.
She added that improvements in health markers should be recognised as an important measure of success, rather than focusing only on the amount of weight lost.
Changing the way success is measured
Healthcare professionals say public discussions about GLP-1 medications often focus heavily on appearance and rapid weight reduction, while overlooking the broader health improvements these treatments may provide.
Dr Yousef Said, Medical Director at Metabolic, said one of the most common misunderstandings among patients is the belief that the number shown on a scale is the only way to judge whether treatment is effective.
He explained that many people begin therapy expecting continuous and dramatic weight loss. When their progress slows down or reaches a temporary plateau, they may assume the medication is no longer working. However, doctors say important changes may continue happening internally even when visible weight changes become slower.
According to Dr Said, improvements such as more stable blood sugar levels, healthier liver function, better kidney-related outcomes, lower blood pressure, and improved sleep quality can represent meaningful progress even if weight loss is not immediately noticeable.
Dr Shah also highlighted the importance of helping patients understand that successful treatment should be evaluated through overall health improvements rather than appearance alone.
She said many individuals naturally focus on quick physical changes, but long-term success should be based on improved metabolic health, better body composition, and reduced risk of disease.
Doctors believe patients need more education about how these medications work and what outcomes should realistically be expected. They emphasise that improving health involves multiple factors and cannot always be measured through weight alone.
Importance of professional guidance
Although GLP-1 therapies have shown promising results, specialists warn that they should not be viewed as a quick solution or used without medical supervision.
Dr Shah raised concerns about people using these medications without proper evaluation, particularly when the goal is only cosmetic weight loss. She explained that incorrect use, unsuitable dosing, or rapid increases in dosage can increase the risk of side effects.
She also noted that some individuals may have existing health conditions that make these treatments unsuitable, which is why medical assessment is necessary before starting therapy.
Dr Said said healthcare providers are increasingly seeing patients who have tried GLP-1 medications independently without structured support. In many cases, these individuals may not achieve the results they expect because they lack proper monitoring, medical guidance, and a personalised treatment plan.
He explained that the medication itself is only one part of the process. Without regular follow-up, health assessments, and lifestyle support, patients may not experience the full potential benefits of treatment.
Lifestyle remains a key part of treatment
Doctors stress that GLP-1 medications should complement healthy lifestyle choices rather than replace them.
Dr Shah explained that lasting improvements require a combination of medical treatment and positive lifestyle changes. She highlighted the importance of maintaining a balanced diet, engaging in strength-based exercise, staying physically active, and developing healthy sleep routines.
She said medication can provide valuable support, but sustainable results depend on long-term habits and consistent care.
While research continues to show strong evidence supporting GLP-1 therapies for weight management, blood sugar control, and reducing certain health risks, experts say careful patient assessment remains essential.
Doctors believe that selecting the right patients, providing proper education, and maintaining ongoing medical supervision are crucial to achieving safe and effective outcomes.
As scientific understanding of GLP-1 treatments continues to grow, experts say the role of these medications is becoming broader. They are increasingly being viewed not only as tools for weight reduction but also as treatments that may influence several aspects of metabolic health.
The emerging message from researchers and clinicians is that the impact of these therapies cannot be measured only by changes on a weighing scale. Their true value may lie in their ability to support wider improvements throughout the body, helping patients achieve better health outcomes over time.
